Picture loading failed.

Pre-Made Tovetumab biosimilar, Whole mAb, Anti-PDGFRA Antibody: Anti-CD140A/PDGFR-2/PDGFR2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Tovetumab is an anti-PDGFRa monoclonal antibody designed for the treatment of cancer. It was developed by MedImmune, and trialed for use in glioblastoma and non-small cell lung cancer. Development was discontinued in 2013.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-590-1mg 1mg 3090
GMP-Bios-ab-590-10mg 10mg Inquiry
GMP-Bios-ab-590-100mg 100mg Inquiry
GMP-Bios-ab-590-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Tovetumab biosimilar, Whole mAb, Anti-PDGFRA Antibody: Anti-CD140A/PDGFR-2/PDGFR2 therapeutic antibody
INN Name Tovetumab
TargetPDGFRA
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG2
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2013
Year Recommended2014
CompaniesCambridge Antibody Technology;MedImmune
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedGlioblastoma;Non-small cell lung cancer;Solid tumours
Development Techna